trending Market Intelligence /marketintelligence/en/news-insights/trending/F0jmS6wL6-bNSkeJlSsnBw2 content esgSubNav
In This List

T2 Biosystems secures BARDA funding to develop diagnostics for sepsis

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


T2 Biosystems secures BARDA funding to develop diagnostics for sepsis

T2 Biosystems Inc. said Sept. 10 that it will receive up to $69 million from the U.S. government to develop its portfolio of diagnostics for sepsis-causing pathogens and antibiotic-resistance genes.

The U.S. Biomedical Advanced Research and Development Authority, or BARDA, will initially provide the company $6 million during the base period. BARDA will then have the right to exercise seven option periods and will provide up to an additional $63 million over the duration of the contract. T2 Biosystems, which develops diagnostic products, will be responsible for a certain portion of expenses as part of the cost-sharing agreement.

The performance period under the contract will last until August 2024, if all option periods are exercised by BARDA.

BARDA is a division of the U.S. Department of Health and Human Services tasked with the procuring and developing countermeasures against bioterrorism, including chemical, nuclear and radiological threats, as well as pandemic influenza and emerging diseases.